NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

Mines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...

Short interest in Mainz Biomed NV (NASDAQ:MYNZ) decreased during the last reporting period, falling from 1.70M to 1.52M. This put 8.25% of the company's publicly available shares short.

Mainz Biomed (MYNZ) announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by ...

BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of ...

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...

Mainz Biomed (MYNZ) announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to ...

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company ...

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.